Bio-Techne Quarterly Cash Flow Statement
NASDAQ: TECHHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Bio-Techne free cash flow
In the quarter ended Jun 30, 2026, Bio-Techne generated $95.4 million of operating cash flow and spent $8.5 million on capital expenditures. That left free cash flow of $86.9 million, a free-cash-flow margin of 27.1% of revenue. Free cash flow was down 6.8% from the prior year's $93.3 million.
Bio-Techne returned $54.1 million to shareholders: $12.5 million in dividends and $41.7 million in share repurchases, equal to 62% of free cash flow. Free cash flow covered dividend payments 7.0 times.
Summary generated from market data by MetaCap's automated system. Methodology
Bio-Techne cash flow statement (quarterly)
| Quarter (USD) | Q4 20262026-06-30 | Q3 20262026-03-31 | Q2 20262025-12-31 | Q1 20262025-09-30 | Q4 20252025-06-30 | Q3 20252025-03-31 | Q2 20252024-12-31 | Q1 20252024-09-30 | Q4 20242024-06-30 | Q3 20242024-03-31 | Q2 20242023-12-31 | Q1 20242023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 54.62M | 51.05M | 38.01M | 38.19M | -17.68M | 22.59M | 34.89M | 33.60M | 40.59M | 49.06M | 27.46M | 50.99M |
| Net Income growth (YoY) | — | +125.99% | +8.94% | +13.65% | -143.55% | -53.96% | +27.03% | -34.11% | -46.23% | -30.13% | -45.08% | -43.17% |
| Depreciation & Amortization | 24.14M | 24.17M | 24.71M | 24.34M | 27.11M | 27.57M | 27.08M | 28.14M | 28.06M | 27.31M | 27.80M | 28.54M |
| Stock-Based Compensation | 5.23M | 10.49M | 13.96M | 11.68M | 4.55M | 11.39M | 14.71M | 10.18M | 7.06M | 8.13M | 12.75M | 10.09M |
| Change in Working Capital | 7.54M | -22.67M | -6.99M | 6.28M | 8.94M | -16.11M | 1.35M | 7.85M | -3.93M | -21.19M | 8.45M | 7.69M |
| Operating Cash Flow | 95.42M | 86.66M | 82.41M | 27.59M | 98.20M | 41.12M | 84.35M | 63.89M | 75.50M | 80.99M | 83.12M | 59.38M |
| Capital Expenditures | -8.48M | -9.09M | -5.92M | -5.36M | -4.89M | -10.12M | -6.82M | -9.17M | -17.98M | -16.44M | -14.86M | -13.59M |
| Investing Cash Flow | -7.06M | -5.82M | -5.92M | 605.00K | 406.00K | -8.87M | -5.03M | -21.68M | -8.81M | -16.44M | -23.67M | -154.11M |
| Dividends Paid | -12.48M | -12.52M | -12.47M | -12.44M | -12.39M | -12.58M | -12.74M | -12.69M | -12.63M | -12.58M | -12.56M | -12.65M |
| Share Repurchases | -41.65M | 0 | 0 | -24.00K | -100.06M | -100.05M | — | — | 0 | 0 | — | — |
| Financing Cash Flow | -33.21M | -42.72M | -48.99M | -44.20M | -90.45M | -68.05M | -83.84M | -11.57M | -60.09M | -52.42M | -81.40M | 71.51M |
| Net Change in Cash | 54.89M | 36.94M | 27.92M | -17.22M | 21.52M | -36.88M | -9.99M | 35.75M | 11.88M | 9.78M | -18.53M | -31.91M |
| Free Cash Flow | 86.94M | 77.58M | 76.49M | 22.22M | 93.31M | 31.00M | 77.53M | 54.72M | 57.52M | 64.55M | 68.25M | 45.79M |
This table shows 12 quarterly periods of Bio-Techne's cash flow statement, from Q4 2026 back to Q1 2024, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow TECH's reporting calendar. What is a cash flow statement?